Document is current
Any future updates will be listed below
-
Authors
Andries, Vanessa
De Keuckelaere, Evi
Staes, Katrien
Hochepied, Tino
Taminau, Joachim
Lemeire, Kelly
Birembaut, Philippe
Berx, Geert
van Roy, Frans https://orcid.org/0000-0003-4358-1039
-
Funding
Funding for this research was provided by:
Stichting Tegen Kanker (2012-191, B/13590)
Fonds Wetenschappelijk Onderzoek (G.0235.10N)
Federaal Wetenschapsbeleid (IAP7/07)
Universiteit Gent (Concerted Research Actions BOF08/GOA/019)
- License Information
-
More Information
Article History
Received: 24 October 2018
Accepted: 6 June 2019
First Online: 17 June 2019
Ethics approval
: Mouse experiments were performed in accordance with the Ethics Committee of the Faculty of Science of Ghent University, Belgium. All procedures were carried out under an approved project license (numbers EC2013–013, EC2014–017, EC2014–018 and EC2014–059) and were meeting the requirements of the European Directive 2010/63/EU. See Additional files andfor details. Written informed consent was obtained from Dr. A.-K. Perl (Cincinnati Children’s Hospital Medical Center, Ohio, USA) for the use of CCSP-rtTA/TetO-Cre transgenic mice, and from Dr. J. Jonkers (Netherlands Cancer Institute, Amsterdam, The Netherlands) for the use of p53<sup>fl/fl</sup> mice.
: The authors declare that they have no competing interests.
